Guoxin Securities released a research report on April 15 stating that it gave Zhaoyan New Pharmaceutical (603127.SH) a purchase rating. The main reasons for the rating include: 1) revenue is basically flat throughout the year, and the profit side is under pressure in the short term; 2) the company continues to promote an integrated layout to enhance core business capabilities; 3) the number of projects in the segment continues to grow, and the market share maintains an advantage; 4) there are plenty of orders in hand, and the expansion of production capacity and personnel ensures order execution. (Mainichi Keizai Shimbun)